Patent Application
20080214600
This invention relates to new therapeutically useful quinuclidine derivatives, to some processes for their preparation and to pharmaceutical compositions containing them.
The novel structures according to the invention are antimuscarinic agents with a potent and long lasting effect. In particular, these compounds show high affinity for muscarinic M3 receptors. This subtype of muscarinic receptor is present in glands and smooth muscle and mediates the excitatory effects of the parasympathetic system on glandular secretion and on the contraction of visceral smooth muscle (Chapter 6, Cholinergic Transmission, in H. P. Rang et al., Pharmacology, Churchill Livingstone, New York, 1995).
M3 antagonists are therefore known to be useful for treating diseases characterised by an increased parasympathetic tone, by excessive glandular secretion or by smooth muscle contraction (R. M. Eglen and S. S. Hegde, (1997), Drug News Perspect., 10(8):462-469).
Examples of this kind of diseases are respiratory disorders such as chronic obstructive pulmonary disease (COPD), bronchitis, bronchial hyperreactivity, asthma, cough and rhinitis; urological disorders such as urinary incontinence, pollakiuria, neurogenic or unstable bladder, cystospasm and chronic cystitis; gastrointestinal disorders such as irritable bowel syndrome, spastic colitis, diverticulitis and peptic ulceration; and cardiovascular disorders such as vagally induced sinus bradycardia (Chapter 7, Muscadinic Receptor Agonists and Antagonists, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th edition, McGraw Hill, New York, 2001).
The compounds of the invention can be used alone or in association with other drugs commonly regarded as effective in the treatment of these diseases. For example, they can be administered in combination with β2-agonists, steroids, antiallergic drugs, phosphodiesterase IV inhibitors and/or leukotriene D4 (LTD4) antagonists for simultaneous, separate or sequential use in the treatment of a respiratory disease. The claimed compounds are useful for the treatment of the respiratory diseases detailed above in association with β2-agonists, steroids, antiallergic drugs or phosphodiesterase IV inhibitors.
Compounds with related structures have been described as anti-cholinergic and/or anti-spasmodics agents in several patents.
For example, FR 2012964 describes quinuclidinol derivatives of the formula
in which R is H, OH or an alkyl group having 1 to 4 carbon atoms; R1 is a phenyl or thienyl group; and R2 is a cyclohexyl, cyclopentyl or thienyl group, or, when R is H, R1 and R2 together with the carbon atom to which they are attached, form a tricyclic group of the formula:
in which X is —O—, —S— or —CH2—,
or an acid addition or quaternary ammonium salt thereof.
In U.S. Pat. No. 4,465,834 a class of anticholinergic drugs having the formula
are described, in which R1 is a carbocyclic or branched aliphatic group of 3 to 8 carbon atoms (such as phenyl, cyclohexyl, cyclopentyl, cyclopropyl, cycloheptyl, and isopropyl), R2 is a branched or linear aliphatic group containing 3 to 10 carbon atoms with 1 or 2 olefinic or acetylenic bonds, or is a phenylethinyl, a styryl, or an ethynyl group, and R3 is an alkyl or cyclic group of 4 to 12 carbon atoms containing a tertiary amino nitrogen. The compounds of the invention are also claimed as either the free base or the acid-addition and quaternary ammonium salt forms thereof.
In U.S. Pat. No. 4,843,074 products of formula
are described, wherein X=H, halogen, lower alkyl, lower alkoxy, hydroxy and R=morpholinyl, thiomorpholinyl, piperidinyl, 1,4-dioxa-8-azaspiro[4,5]decanyl, 4-(2,6-dimethylmorpholinyl), 4-ketopiperidinyl, 4-hydroxypiperidinyl, 4-substituted piperazinyl. The lower alkyl halide quaternary salts and pharmaceutically acceptable acid addition salts are included in the invention.
U.S. Pat. No. 4,644,003 describes esters of 3-quinuclidinol of alpha disubstituted glycolic acids
and their pharmaceutically acceptable salts,
where R is phenyl, unsubstituted or substituted with up to three substituents including alkoxy, halogen, nitro, amino, alkylamino, dialkylamino, acylamino, and trifluoromethyl; and wherein R1 is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, alkyloxyalkyl, cycloalkyloxyalkyl, haloalkyl or haloalkenyl.
In WO 92/04346 are described compounds of formula
and their pharmaceutically acceptable salts, where X is a phenyl (optionally substituted) or a thienyl group and “Het” is either (a) a five membered nitrogen-containing heterocyclic group, (b) an oxadiazolyl or thiadiazolyl group, or (c) a six membered nitrogen-containing heterocyclic group, and m is 1 or 2. (For a more detailed description, see the above mentioned publication)
Azoniabicyclic compounds of a general structure related to the compounds of the invention are disclosed in WO 01/04118 and WO 02/053564.
WO 2004/096800 is directed to esters of quaternized 3-quinuclidinols of formula
wherein the quaternising group (R4) is a C1-8 alkyl group substituted, among others, by —OR11, —OCO—R13 or —COO—R14 wherein R11 is hydrogen, C1-8-alkyl, C1-8-alkyl-C1-8-alkoxy or C1-8-alkyl-O—C3-15 carbocyclic group, R13 is C1-8-alkyl or a C3-15-carbocyclic group and R14 is hydrogen, a C3-15-carbocyclic group, C1-8-alkenyl, or C1-8-alkyl optionally substituted by a C3-15-carbocyclic group and discloses specifically, among others, the compounds: 1-Allyloxycarbonylmethyl-3-(2-hydroxy-2,2-di-thiophen-2-yl-acetoxy)-1-azonia-bicyclo-[2.2.2]octane and 1-carboxymethyl-3-(2-hydroxy-2,2-di-thiophen-2-yl-acetoxy)-1-azonia-bicyclo-[2.2.2]octane.
The present invention provides new quinuclidine ester derivatives with potent antagonist activity at muscarinic M3 receptors which have the chemical structure described in formula (I):
B represents a hydrogen atom or a group selected from —R1, —OR1, hydroxy, —O(CO)R1, cyano and an optionally substituted non-aromatic heterocyclyl containing one or more heteroatoms, wherein
Other aspects of the present invention are: a) a process for the preparation of the compounds of formula (I), b) pharmaceutical compositions comprising an effective amount of said compounds, c) the use of said compounds in the manufacture of a medicament for the treatment of respiratory, urinary and/or gastrointestinal diseases; and d) methods of treatment of respiratory, urinary and/or gastrointestinal diseases, which methods comprise the administration of the compounds of the invention to a subject in need of treatment.
As used herein the term lower alkyl embraces optionally substituted, linear or branched radicals having from 1 to 8, preferably 1 to 6 and more preferably 1 to 4 carbon atoms.
Examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl and tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, isopentyl, 1-ethylpropyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, n-hexyl or 1-ethylbutyl, 2-ethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2-methylpentyl, 3-methylpentyl, trifluoromethyl and iso-hexyl radicals.
As used herein, the term lower alkenyl embraces optionally substituted, linear or branched, mono or polyunsaturated radicals having 2 to 8, preferably 2 to 6 and more preferably 2 to 4 carbon atoms. In particular it is preferred that the alkenyl radicals are mono or diunsaturated.
Examples include vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl and 4-pentenyl radicals.
As used herein, the term lower alkynyl embraces optionally substituted, linear or branched, mono or polyunsaturated radicals having 2 to 8, preferably 2 to 6 and more preferably 2 to 4 carbon atoms. In particular, it is preferred that the alkynyl radicals are mono or diunsaturated.
Examples include 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl and 3-butynyl radicals.
As used herein, the term lower alkoxy embraces optionally substituted, linear or branched oxy-containing radicals each having alkyl portions of 1 to 8 carbon atoms, preferably 1 to 6 and more preferably 1 to 4 carbon atoms.
Preferred alkoxy radicals include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, sec-butoxy, t-butoxy, trifluoromethoxy, difluoromethoxy, hydroxymethoxy, 2-hydroxyethoxy or 2-hydroxypropoxy.
As used herein, the term cycloalkyl embraces saturated carbocyclic radicals and, unless otherwise specified, a cycloalkyl radical typically has from 3 to 7 carbon atoms.
A cycloalkyl radical is typically unsubstituted or substituted with 1, 2 or 3 substituents which may be the same or different. When a cycloalkyl radical carries 2 or more substituents, the substituents may be the same or different.
Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. It is preferably cyclopropyl, cyclopentyl or cyclohexyl.
As used herein, the term cycloalkenyl embraces partially unsaturated carbocyclic radicals and, unless otherwise specified, a cycloalkenyl radical typically has from 3 to 7 carbon atoms.
A cycloalkenyl radical is typically unsubstituted or substituted with 1, 2 or 3 substituents which may be the same or different. When a cycloalkenyl radical carries 2 or more substituents, the substituents may be the same or different.
Examples include cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl. It is preferably cyclopentenyl or cyclohexenyl.
As used herein, the term heterocyclyl radical embraces typically a non-aromatic, saturated or unsaturated C3-C10 carbocyclic ring, such as a 5, 6 or 7 membered radical, in which one or more, for example 1, 2, 3 or 4 of the carbon atoms preferably 1 or 2 of the carbon atoms are replaced by a heteroatom selected from N, O and S excluding the group benzo[1,3]dioxolyl. Saturated heterocyclyl radicals are preferred. A heterocyclic radical may be a single ring or two or more fused rings wherein at least one ring contains a heteroatom. When a heterocyclyl radical carries 2 or more substituents, the substituents may be the same or different.
An heterocyclyl radical is typically unsubstituted or substituted with 1, 2 or 3 substituents which may be the same or different. The substituents are preferably selected from halogen atoms, preferably fluorine atoms, hydroxy groups, oxo groups, alkyl groups having from 1 to 4 carbon atoms and alkoxy groups having from 1 to 4 carbon atoms. When an heterocyclyl radical carries 2 or more substituents, the substituents may be the same or different.
Examples of non-aromatic heterocyclic radicals include piperidyl, pyrrolidinyl, pyrrolinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrazolinyl, pirazolidinyl, quinuclidinyl, imidazolidinyl, oxiranyl and azaridinyl.
As used herein, the term halogen atom embraces chlorine, fluorine, bromine or iodine atom typically a fluorine, chlorine or bromine atom, most preferably chlorine or fluorine.
As used herein when a group or radical is said to be optionally substituted it is meant that it may have some of its hydrogen atoms replaced by up to 3 substituents selected from the group comprising halogen atoms, hydroxy groups, alkyl groups having from 1 to 4 carbon atoms and alkoxy groups having from 1 to 4 carbon atoms. When the group carries more than one substituent it is preferred that the substituents are bound to different atoms in the group.
As used herein, the term mono or polyvalent acid embraces pharmaceutically acceptable acids include both inorganic acids, for example hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic, hydroiodic and nitric acid and organic acids, for example citric, fumaric, maleic, malic, mandelic, ascorbic, oxalic, succinic, tartaric, benzoic, formic, acetic, trifluoroacetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid.
Wherein the compounds of the present invention contain one or more chiral centers all configurations of the chiral center are covered and in particular enantiomers or diastereomers arising from the multiple configurations are within the scope of the present invention. Non limiting examples of the chiral centers which may be present in the compounds of the present invention are the quaternary nitrogen atom of the azoniabicyclic ring, the carbon atom in the azoniabicyclic ring to which the group D-COO— is attached and the carbon atom by which group D is linked to the ester group.
In a preferred embodiment of the present invention preferred compounds of formula (I) are those wherein B represents a hydrogen atom or a group selected from —R1, —OR1, hydroxy, —O(CO)R1, cyano and an optionally substituted non-aromatic heterocyclyl containing one or more heteroatoms, wherein
In an embodiment of the present invention preferred compounds of formula (I) are those wherein A represents a group selected from —CH2—, —CH═CR3—, —CR3═CH—, —CR3R4—, —O—, —O—(CH2)2—O— wherein R3 and R4 each independently represent a hydrogen atom or a C1-8 alkyl group;
In another embodiment of the present invention preferred compounds of formula (I) are those wherein B is selected from the group consisting of hydrogen atoms, hydroxy groups, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C3-C8 cycloalkyl groups and non-aromatic heterocyclyl groups substituted at least with a hydroxy group.
In still another embodiment of the present invention the azoniabicyclo group is substituted on the nitrogen atom with a group selected from allyl, 4-methylpent-3-enyl, isopropyl, cyclopropylmethyl, isobutyl, heptyl, cyclohexylmethyl, 34-cyclohexylpropyl, 3,7-dimethylocta-(E)-2,6-dienyl, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, 6-hydroxyhexyl, 2-ethoxyethyl, 2-(2-hydroxyethoxy)ethyl, 2-(2-methoxyethoxy)ethyl, oxiranylmethyl, 2-[1,3]dioxolan-2-ylethyl, 2-[2-(2-hydroxyethoxy)-ethoxy]ethyl, 3-[1,3]dioxolan-2-ylpropyl, 2-ethoxycarbonylethyl, 3-ethoxycarbonylpropyl, 4-ethoxycarbonylbutyl, 4-acetoxybutyl, 2-cyanoethyl, 3-cyanopropyl, 4-cyanobutyl, 6-cyanohexyl, 4,4,4-trifluorobutyl, 3-(4 hydroxypiperidin1-yl)propyl and 4-(4-hydroxypiperidin1-yl)butyl. More preferably the azoniabicyclo group is substituted on the nitrogen atom with a group selected from allyl, 4 methylpent-3-enyl, isopropyl, cyclopropylmethyl, isobutyl, heptyl, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, 6-hydroxyhexyl, 2-(2-methoxyethoxy)ethyl, 2-(2-hydroxyethoxy)ethyl, 4-ethoxycarbonylbutyl, 4-acetoxybutyl, 3-cyanopropyl and 4 cyanobutyl. It is particularly preferred that the azoniabicyclo group is substituted on the nitrogen atom with a group selected from allyl, 4-methylpent-3-enyl and n-heptyl, more preferably with a group selected from allyl and n-heptyl and most preferably with an allyl group.
In another embodiment of the present invention p is 2.
In still another embodiment of the present invention the substitution in the azoniabicyclic ring is in the 3 position and includes all possible configurations of the asymmetric carbon. More preferably the configuration of carbon 3 in the azoniabicyclic ring is R configuration.
In another embodiment of the present invention R5 represents an unsubstituted phenyl, 2-thienyl, 3-thienyl, 2-furyl or 3-furyl group.
In another embodiment of the present invention R6 represents a 2-thienyl, 3-thienyl, 2-furyl 3-furyl or cyclopentyl group.
In still another embodiment of the present invention the group of formula —O—CO—C(R5)(R6)(R7) represents a group selected from 2,2-dithien-2-ylacetoxy, 2,2-dithien-2-ylpropionyloxy, 2-hydroxy-2,2-dithien-2-ylacetoxy, 2-hydroxy-2-phenyl-2-thien-2-ylacetoxy, 2-fur-2-yl-2-hydroxy-2-phenylacetoxy, 2-fur-2-yl-2-hydroxy-2-thien-2-ylacetoxy, (2*)-2-hydroxy-2,3-diphenylpropionyloxy, 2-hydroxy-2-thien-2-ylpent-4-enoyloxy, (2S)-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy and (2R)-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy. More preferably the group —O—CO—C(R5)(R6)(R7) represents a group selected from 2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy; 2,2-dithien-2-ylacetoxy, 2-hydroxy-2,2-dithien-2-ylacetoxy, 2,2-dithien-2-ylpropionyloxy; 2-hydroxy-2-phenyl-2-thien-2-ylacetoxy, 2-fur-2-yl-2-hydroxy-2-thien-2-ylacetoxy and 2-fur-2-yl-2-hydroxy-2-phenylacetoxy. Still more preferably the group —O—CO—C(R5)(R6)(R7) represents a group selected from 2-hydroxy-2,2-dithien-2-ylacetoxy and (2S)-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetoxy and most preferably a 2-hydroxy-2,2-dithien-2-ylacetoxy group.
In still another embodiment of the present invention the group of formula D-COO— represents a group selected from 9-methyl-9H-fluorene-9-carbonyloxy, 9-hydroxy-9H-fluorene-9-carbonyloxy, 9H-xanthene-9-carbonyloxy, 9-methyl-9H-xanthene-9-carbonyloxy, 9-hydroxy-9H-xanthene-9-carbonyloxy, 9,10-dihydroanthracene-9-carbonyloxy and 10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carbonyloxy. More preferably the group of formula D-COO— represents a group selected from 9-methyl-9H-fluorene-9-carbonyloxy, 9-hydroxy-9H-fluorene-9-carbonyloxy, 9H-xanthene-9-carbonyloxy, 9-methyl-9H-xanthene-9-carbonyloxy and 9-hydroxy-9H-xanthene-9-carbonyloxy and most preferably selected from 9-methyl-9H-xanthene-9-carbonyloxy and 9-hydroxy-9H-xanthene-9-carbonyloxy.
In another embodiment of the present invention the carbon substituted by R5, R6 and R7 has R configuration.
In another embodiment of the present invention the carbon substituted by R5, R6 and R7 has S configuration.
The following compounds are intended to illustrate but not to limit the scope of the present invention:
Of outstanding interest are the compounds:
In another aspect the present invention also provides processes for preparing compounds of formula (I).
The new quaternary ammonium derivatives of general formula (I), may be prepared, as illustrated in the following scheme, by reaction of an alkylating agent of formula (II) with compounds of general formula (III) using two possible methods (a) or (b), described in detail in the experimental section. Method (b) involves the use of solid phase extraction techniques that allow the parallel preparation of several compounds.
In formula (II), W represents any suitable leaving group, preferably a group X− as defined above for the compounds of general formula (I). When W is a leaving group other than X−, the quaternary ammonium salt of formula (I) is produced from the product of method (a) or (b) by an exchange reaction according to standard methods to replace the anion W− with the desired anion X−.
Those compounds of general formula (II) which are not commercially available may be prepared according to standard methods. For example, some examples of compounds of formula (II) wherein A=—O—, —S—, —NR3—, may be obtained by reaction of the corresponding alcohol, thiol or amine derivative, or its sodium or potassium salt, with an alkylating agent of general formula Y—(CH2)m—W, wherein W is as defined above; most preferably W is a halogen atom and Y is a halogen atom or a sulphonate ester. In other examples, compounds of general formula (II) may be synthesised from the corresponding alcohol derivative of general formula (IV) by methods known in the art.
B—(CH2)n-A-(CH2)m—OH (IV)
The compounds of formula (I) and (III) may have one or more asymmetric carbons. All possible stereoisomers, single isomers and mixtures of isomers are also included within the scope of the present invention. The diastereomers of the compounds may be separated by conventional methods, for example by chromatography or crystallisation.
Compounds of formula (III) may be prepared by three different methods, (c), (d), and (e) as is described in the following scheme and detailed in the experimental section.
In the compounds of formula (VI) described in method (c), R10 is a lower alkyl group.
The following compounds of Formula (V) are described in the literature:
Some compounds of general formula (III) where D is a group of formula i), R5 and R6 are as described above and R7 is a hydroxy group, may also be prepared from the glyoxalate esters of general formula (VII) by reaction with the corresponding organometallic derivative as is described in the following scheme and detailed in the experimental section (method (f)).
Compounds of formula (VII) may be prepared from the corresponding glyoxylic acids following the standard methods (c), (d) and (e) or as is described in WO 01/04118 and WO 92/04346.
As is described in the following scheme, compounds of formula (III) where R7 is a —CH2OH group, may also be prepared from the corresponding compound of formula (III), wherein R7 is an H atom, by reaction with formaldehyde in basic conditions (see method (g), WO 93/06098 and WO02/053564).
The structures of the prepared compounds were confirmed by 1H-NMR and MS. The NMR were recorded using a Varian 300 MHz instrument and chemical shifts are expressed as parts per million (δ) from the internal reference tetramethyl silane. Their purity was determined by HPLC, using reverse phase chromatography on a Waters instrument. Molecular ions were obtained by electrospray ionization mass spectrometry on a Hewlett Packard instrument.
Optical rotations were measured using a PERKIN-ELMER 241 MC polarimeter.
The following examples are intended to illustrate but not to limit the experimental procedures that have been described before.
250 mg (0.75 mmol) of 9-Hydroxy-9H-fluorene-9-carboxylic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (Intermediate I-3) were dissolved in 4 ml of acetonitrile and 6 ml of CHCl3. To this solution was added 0.59 ml (0.67 g, 3.75 mmol) of 1-bromoheptane. After stirring for 72 h at room temperature under a N2 atmosphere, solvents were evaporated. Ether was added and the mixture stirred. The solid obtained was washed several times with ether and filtered. The yield was 330 mg (85.5%) of the title compound.
m.p.: 214.9-216.6° C.
MS [M-Br]+: 434
1H-NMR (300 MHz, DMSO-d6) δ ppm: 0.88 (t, 3H), 1.12-1.70 (m, 12H), 1.70-1.93 (m, 2H), 2.04 (m, 1H), 2.78 (m, 1H), 2.96-3.18 (m, 3H), 3.18-3.48 (m, 3H), 3.77 (m, 1H), 5.01 (m, 1H), 6.84 (s, 1H, OH), 7.34 (m, 2H), 7.45 (m, 2H), 7.61 (m, 2H), 7.84 (d, 2H).
0.5 g (0.0015 mol) of 9-Hydroxy-9H-fluorene-9-carboxylic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (Intermediate I-3) were dissolved in 10 ml of acetonitrile and 15 ml of CHCl3. To this solution 1.02 ml (1.37 g, 0.0075 mol) of 1-bromo-2-(2-methoxyethoxy)ethane were added and the mixture was stirred at room temperature during 96 hours. After this time a new portion (0.2 ml, 0.27 g, 0.0015 mol) of 1-bromo-2-(2-methoxyethoxy)ethane was added and the mixture stirred at room temperature during 24 hours more. After this time solvents were evaporated. Ether was added and the mixture stirred to obtain a solid, the solvent was extracted and more ether was added. This procedure was repeated several times in order to eliminate the residual alkylating agent. Finally the suspension was filtered and the solid obtained washed with ether and dried. The yield was 610 mg (78.2%) of the title compound.
m.p.: 194° C.
MS [M-Br]+: 438
1H-NMR (300 MHz, DMSO-D6) δ ppm: 1.44 (m, 1H), 1.64 (m, 1H), 1.85 (m, 2H), 2.09 (m, 1H), 2.93 (m, 1H), 3.18-3.28 (m, 1H), 3.26 (s, 3H), 3.30-3.60 (m, 9H), 3.73 (m, 2H), 3.88 (m, 1H), 5.00 (m, 1H), 6.83 (s, 1H, OH), 7.35 (m, 2H), 7.45 (m, 2H), 7.61 (m, 2H), 7.83 (d, 2H).
1.05 g (3 mmol) of 9-Methyl-9H-xanthene-9-carboxylic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester were dissolved in 15 ml of THF and 0.544 g (4.5 mmol) of 3-bromoprop-1-ene (allyl bromide) were added. The mixture was refluxed during 4 hours and allowed to continue stirring at room temperature for 15 hours. After this time the solvent was concentrated until ¼ part of the initial volume. Ether was added and the mixture stirred during 20 min to obtain a solid, the solvent was extracted and more ether was added. This procedure was repeated several times in order to eliminate the residual alkylating agent. Finally the suspension was filtered and the solid obtained washed with ether and dried. The yield was 1.04 g (73.8%) of the title compound.
m.p.: 64.3-67.8° C.
MS [M-Br]+: 390
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.35 (m, 1H), 1.65 (m, 1H), 1.73-1.91 (m, 2H), 1.89 (s, 3H), 2.11 (m, 1H), 2.75 (m, 1H), 3.00 (m, 1H), 3.15-3.45 (m, 3H), 3.70-3.90 (m, 3H), 5.03 (m, 1H), 5.50-5.65 (m, 2H), 5.86 (m, 1H), 7.12-7.19 (m, 4H), 7.35 (m, 2H), 7.42 (m, 2H).
60 mg (0.17 mmol) of 2-Hydroxy-2,2-dithien-2-ylacetic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester were dissolved in 0.7 ml of DMSO. To this solution 161 mg (0.128 ml, 0.85 mmol) of 7-bromoheptanenitrile dissolved in 0.3 ml of DMSO were added. After stirring overnight at room temperature, the mixture was purified by solid phase extraction with a cation exchange Mega Bond Elut cartridge, previously conditioned at pH=7.5 with 0.1M NaH2PO4 buffer. The reaction mixture was applied to the cartridge an washed first with 2 ml of DMSO and then three times with 5 ml of CH3CN, rinsing away all the starting materials. The ammonium derivative was eluted with 5 ml of 0.03 M TFA solution in CH3CN:CHCl3 (2:1). This solution was neutralized with 300 mg of poly(4-vinylpyridine), filtered and evaporated to dryness. The yield was 19.1 mg (19.6%) of the title compound.
MS [M-CF3COO]+: 459
Methyl ester derivatives of general formula (VI) may be prepared by standard methods of esterification from the corresponding carboxylic acid or according to procedures described in literature: FR 2012964; Larsson, L. et al., Acta Pharm, Suec. (1974), 11 (3), 304-308; Nyberg, K. et al., Acta Chem. Scand. (1970), 24, 1590-1596; Cohen, V. I. et al., J. Pharm. Sciences (1992), 81, 326-329; WO 01/04118, WO 02/053564 and references cited therein.
1.67 g (0.007 mol) of 2,2-Dithien-2-ylacetic acid methyl ester were dissolved in 40 ml of toluene. To this solution were added 1.04 g (0.0082 mol) of (3R)-3-hydroxy-1-azabicyclo[2.2.2]octane and 0.14 g (0.0035 mol) of HNa (60% dispersion mineral oil). The mixture was refluxed during 10 min and, after this time, refluxed with continuous removal of distillate with replacement with fresh toluene when necessary for two hours. The cooled mixture was extracted with 2N HCl acid, the aqueous layer washed with ethyl acetate, basified with K2CO3 and extracted with CHCl3. The organic layer was washed with a small volume of water, dried over Na2SO4 and evaporated. The oil obtained (2 g) was purified by chromatography on silica gel eluting with CHCl3/MeOH/NH4OH 95:5:0.5. Appropriate fractions were combined and evaporated to obtain the title product as an oil (0.82 g, 35%).
This product was solidified by formation of the fumarate salt. A portion of 0.43 g (0.00128 mol) of the oil obtained (free base) was treated with fumaric acid in acetone/diethyl ether to obtain a solid which was filtered and washed with ether. The yield was 0.44 g of the fumarate salt. 2,2-Dithien-2-ylacetic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester fumarate salt:
m.p.: 122° C.
MS [M free base+1]+: 334
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.44 (m, 1H), 1.64 (m, 3H), 2.03 (m, 1H), 2.62-2.98 (m, 5H), 3.30 (m, 1H), 4.89 (m, 1H), 5.84 (s, 1H), 6.54 (s, 2H), 7.01 (m, 2H), 7.09 (m, 2H), 7.48 (m, 2H).
2,2-Dithien-2-ylacetic acid methyl ester was prepared by reduction of 2-Hydroxy-2,2-dithien-2-ylacetic acid methyl ester following the method described in F. Leonard; I. Ehranthal, J. Am. Chem. Soc, Vol 73, pag 2216-2218, (1951).
0.86 g (0.0034 mol) of 2,2-Dithien-2-ylpropionic acid methyl ester were dissolved in 25 ml of toluene. To this solution were added 0.51 g (0.004 mol) of (3R)-3-hydroxy-1-azabicyclo[2.2.2]octane and 0.055 g (0.0014 mol) of HNa (60% dispersion mineral oil). The mixture was refluxed during 10 minutes and, after this time, refluxed with continuous removal of distillate with replacement with fresh toluene when necessary for 1.5 hours. The cooled mixture was extracted with 2N HCl acid, the aqueous layer washed with ethyl acetate, basified with K2CO3 and extracted with CHCl3. The organic layer was washed with a small volume of water, dried over Na2SO4 and evaporated. The yield was 1.11 g of the title product as an oil (94.07%).
GC/MS [M]+: 347
This product was solidified by formation of the oxalate salt: 0.25 g of the free base (0.00072 mol) were treated with oxalic acid (0.065 g, 0.00072 mol) in acetone/diethyl ether. A solid was obtained which was filtered and washed with ether. The yield was 0.25 g (79.4%).
2,2-Dithien-2-ylpropionic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester oxalate salt:
m.p.: 126.7-128.6° C.
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.61 (m, 2H), 1.83 (m, 2H), 2.08 (s, 3H), 2.19 (m, 1H), 2.88 (m, 1H), 2.95-3.28 (m, 4H), 3.61 (m, 1H), 5.09 (m, 1H), 7.01 (m, 2H), 7.07 (m, 2H), 7.51 (m, 2H), 9.15 (br. s., 2H).
2,2-Dithien-2-ylpropionic acid methyl ester was prepared by a standard method of esterification from 2,2-Dithien-2-ylpropionic acid, prepared as described in M. Sy et al; Bull. Soc. Chim. Fr.; Vol 7, 2609-2611, (1957).
1.0 g (0.0042 mol) of 9-Hydroxy-9H-fluorene-9-carboxylic acid methyl ester were dissolved in 25 ml of toluene. To this solution were added 0.67 g (0.0053 mol) of (3R)-3-hydroxy-1-azabicyclo[2.2.2]octane and 0.064 g (0.0016 mol) of HNa (60% dispersion in mineral oil). The mixture was refluxed during 15 min and, after this time, refluxed with continuous removal of distillate with replacement with fresh toluene when necessary for 1.5 hours. The cooled mixture was extracted with 2N HCl acid, the aqueous layer washed with diethyl ether, basified with K2CO3 and extracted with CHCl3. The organic layer was washed with water, dried over Na2SO4 and evaporated. The solid obtained was treated with diethyl ether and filtered. The product obtained was recrystallised from a mixture of CHCl3/diisopropyl ether filtered and washed with diisopropyl ether. The yield was 0.75 g of the title product. (53.2%).
m.p.: 217° C.
MS [M+1]+: 336
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.00 (m, 2H), 1.25-1.50 (m, 2H), 1.60 (m, 1H), 2.0-2.16 (m, 2H), 2.37-2.56 (m, 3H), 2.91 (m, 1H), 4.57 (m, 1H), 6.74 (br. s., 1H, OH), 7.31 (m, 2H), 7.42 (m, 2H), 7.51 (m, 2H), 7.81 (m, 2H).
9-Hydroxy-9H-fluorene-9-carboxylic acid methyl ester was prepared from 9-Hydroxy-9H-fluorene-9-carboxylic acid (commercially available) using a standard method of esterification.
The following compounds of formula (III) have also been prepared according to method (c):
2.15 g of 10,11-Dihydro-5H-dibenzo[a,d]cycloheptene-5-carboxylic acid (9.0 mmol) were dissolved in 40 ml of CHCl3 (ethanol free). The solution was cooled at 0° C. and 0.86 ml of oxalyl chloride (9.9 mmols) and a drop of DMF were added. The mixture was stirred and allowed warm to room temperature. After an hour at this temperature the solvents were evaporated and the residue was dissolved in CHCl3 and evaporated again. This procedure was repeated two times. The obtained oil was dissolved in 20 ml of toluene and added to a solution of 1.26 g (9.9 mmol) of (3R)-3-hydroxy-1-azabicyclo[2.2.2]octane in 40 ml of hot toluene. The reaction mixture was refluxed for 2 hours. After cooling the mixture was extracted with 2N HCl acid. The aqueous layer was basified with K2CO3 and extracted with CHCl3. The organic layer was dried over Na2SO4 and evaporated to dryness. The residue was purified by column chromatography (silica gel, CHCl3:MeOH:NH4OH, 95:5:0.5). The yield was 1.5 g (48%) of the title product.
m.p.: 112-113° C.
CG/MS [M]+: 347
1H-NMR (300 MHz, CDCl3) δ ppm: 1.10-1.35 (m, 2H), 1.40-1.52 (m, 1H), 1.52-1.68 (m, 1H), 1.90 (m, 1H), 2.40-2.60 (m, 2H), 2.60-2.77 (m, 3H), 2.83-2.96 (m, 2H), 3.07-3.19 (m, 1H), 3.25-3.40 (m, 2H), 4.80 (m, 2H), 7.10-7.30 (m, 8H).
10,11-Dihydro-5H-dibenzo[a,d]cycloheptene-5-carboxylic acid was prepared as described in Kumazawa T. et al., J. Med. Chem., (1994), 37, 804-810.
The following compound of formula (III) has also been prepared according to method (d) from the corresponding carboxylic acid:
660 mg (0.00282 mol) of (2R)-2-Cyclohexyl-2-hydroxy-2-phenylacetic acid (obtained as is described in WO 02/053564) were dissolved in 9 ml of DMF. This solution was stirred at room temperature and 548 mg (0.00338 mol) of 1,1′-carbonyldiimidazole were added. The reaction was monitored by TLC (CHCl3/MeOH/AcOH 70:30:2) following the formation of the imidazolide. After 1 hour the reaction was complete. The reaction mixture was cooled to 0° C. and 394 mg (0.0031 mol) of 4-hydroxy-1-azabicyclo[2.2.2]octane and 104 mg (0.00259 mol) of HNa (60% dispersion in mineral oil) were added. After 44 h of stirring at room temperature the reaction mixture was treated with water and extracted three times with diethyl ether. The organic layers were combined, washed with brine and dried over anhydrous magnesium sulphate. The solvent was evaporated and the residue was purified by silica gel column chromatography eluting with CHCl3 to CHCl3/MeOH 15:1. The yield was 300 mg (31%) of the title product.
[α]22D=−27.6° (c=1, CHCl3)
MS: [M+1]+: 344
1H-NMR (300 MHz, CDCl3) δ ppm: 1.0-1.55 (m, 7H), 1.55-1.75 (m, 2H), 1.75-1.85 (m, 1H), 1.85-2.05 (m, 6H), 2.10-2.22 (m, 1H), 2.90-3.10 (m, 6H), 3.60-3.80 (bs, 1H, OH), 7.20-7.40 (m, 3H), 7.57-7.67 (m, 2H).
Benzylmagnesium chloride, 0.00386 mol (1.93 ml of a solution 2M in THF), was added to a solution of 1 g (0.00385 mol) of 2-oxo-2-phenylacetic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, dissolved in 8 ml of THF, at −70° C. under a N2 atmosphere. The mixture was stirred at this temperature for 10 minutes, then warmed to room temperature and diluted with 4 ml more of THF. After 1 h, the reaction mixture was treated with 10% K2CO3 solution and extracted twice with ethyl acetate. The organic phases were combined and dried over Na2SO4. After removal of the solvent, the oil obtained was partitioned between HCl 2N and diethyl ether. The aqueous phase was basified with K2CO3 an extracted with CHCl3. The organic solution was washed with water, dried over Na2SO4 and solvent was evaporated to yield 1.2 g of an oil.
This reaction process was reproduced starting from 2 g (0.0077 mol) of 2-oxo-2-phenylacetic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester and 0.0077 mol of benzylmagnesium chloride (3.85 ml of a solution 2M in THF), to obtain 2.91 g of the final oil.
The total amount of product (4.11 g) was purified by column chromatography (silica gel) eluting with CHCl3/MeOH/NH4OH 99:1:0.1→95:5:0.5. Appropriate fractions were combined to give 1.86 g of a pure product as a solid mixture of diastereomers I-6a and I-6b, which were separated by maceration using diethyl ether/diisopropyl ether.
The 1.86 g of the mixture of diastereomers (I-6) were treated with a mixture of diethyl ether/diisopropyl ether and filtered to give a solid identified as a pure diastereomer.
The yield was 0.87 g (42.6% based on single isomer),
m.p.: 132° C.
MS [M+1]+: 352
1H-NMR (300 MHz, CDCl3) δ ppm: 1.30-1.60 (m, 2H), 1.60-1.90 (m, 2H), 2.05 (m, 1H), 2.20-2.35 (m, 1H), 2.50-2.90 (m, 4H), 3.0-3.15 (m, 1H), 3.25 and 3.60 (dd, 2H), 3.70 (br.s., 1H, OH), 4.70-4.80 (m, 1H), 7.15-7.45 (m, 8H), 7.65-7.75 (m, 2H).
The mother liquors of filtration of the first diastereomer were enriched in the second diastereomer. After evaporation of the solvents, 0.55 g of the residue were treated with diethyl ether and filtered to give a solid identified as the pure second diastereomer. The yield was 0.23 g (11.2% based on single isomer),
m.p.: 107° C.
MS [M+1]+: 352
1H-NMR (300 MHz, CDCl3) δ ppm: 1.20-1.35 (m, 1H), 1.35-1.55 (m, 2H), 1.55-1.70 (m, 1H), 1.80-1.95 (m, 1H), 2.55-2.90 (m, 5H), 3.10-3.20 (m, 1H), 3.25 and 3.60 (dd, 2H), 3.80 (br.s., 1H, OH), 4.65-4.80 (m, 1H), 7.20-7.50 (m, 8H), 7.65-7.75 (m, 2H).
((*): Configuration not assigned, either the (2R)- or the (2S)-isomers of the above compounds may be obtained)
2-oxo-2-phenylacetic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester was prepared as is described in WO 92/04346.
The following compounds of formula (III) have also been prepared following method (f):
Other carboxylic acids of formula D-C(O)OH, whose preparation (or the syntheses of their derivatives methyl ester, chloride or imidazolide) haven't been described in methods (c), (d), (e), and that are not commercially available, could be prepared as is described in the following references:
Also included within the scope of the present invention are pharmaceutical compositions which comprise, as the active ingredient, at least one quinuclidine derivative of general formula (I) in association with a pharmaceutically acceptable carrier or diluent. Preferably the composition is made up in a form suitable for oral administration.
The pharmaceutically acceptable carrier or diluents which are mixed with the active compound or compounds, to form the composition of this invention are well-known per se and the actual excipients used depend inter alia on the intended method of administration of the composition.
Compositions of this invention are preferably adapted for oral administration. In this case, the composition for oral administration may take the form of tablets, film-coated tablets, liquid inhalant, powder inhalant and inhalation aerosol; all containing one or more compounds of the invention; such preparations may be made by methods well-known in the art.
The diluents which may be used in the preparations of the compositions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents, if desired. Tablets or film-coated tablets may conveniently contain between 1 and 500 mg, preferably from 5 to 300 mg of active ingredient. The inhalant compositions may contain between 1 μg and 1,000 μg, preferably from 10 μg to 800 μg of active ingredient. In human therapy, the dose of the compound of general formula (I) depend on the desired effect and duration of treatment; adult doses are generally between 3 mg and 300 mg per day as tablets and 10 μg and 800 μg per day as inhalant composition.
Pharmacological Action
The results on human muscarinic receptors binding and in the test on bronchospasm in guinea pig, were obtained as described below.
Human Muscarinic Receptor Studies.
The binding of [3H]-NMS to human muscarinic receptors was performed according to Waelbroek et al (1990), Mol. Pharmacol., 38: 267-273. Assays were carried out at 25° C. Membrane preparations from stably transfected Chinese hamster ovary-K1 cells (CHO) expressing the genes for the human muscarinic receptors M3 were used.
For determination of IC50, membrane preparations were suspended in DPBS to a final concentration of 89 μg/ml for the M3 subtype. The membrane suspension was incubated with the tritiated compound for 60 min. After incubation the membrane fraction was separated by filtration and the bound radioactivity determined. Non specific binding was determined by addition of 10−4 M atropine. At least six concentrations were assayed in duplicate to generate individual displacement curves.
Our results show that the compounds of the present invention have high affinities for muscarinic M3 receptors, preferably human muscarinic receptors. Preferred compounds of the present invention have an IC50 (nM) value for M3 receptors of less than 50, preferably less than 25, more preferably less than 15 and most preferably less than 10, 8 or 5.
Test on Bronchospasm in Guinea Pig
The studies were performed according to H. Konzett and F. Rössler (1940), Arch. Exp. Path. Pharmacol. 195: 71-74. Aqueous solutions of the agents to be tested were nebulized and inhaled by anaesthetized ventilated male guinea pigs (Dunkin-Hartley). Bronchial response to intravenous acetylcholine challenge was determined before and after drug administration and the changes in pulmonary resistance at several time-points were expressed as percent of inhibition of bronchospasm.
The compounds of the present invention inhibited the bronchospasm response to acetylcholine with high potency and a long duration of action.
From the above described results one of ordinary skill in the art can readily understand that the compounds of the present invention have excellent antimuscarinic activity (M3) and thus are useful for the treatment of diseases in which the muscarinic M3 receptor is implicated, including respiratory disorders such as chronic obstructive pulmonary disease (COPD), bronchitis, bronchial hyperreactivity, asthma, cough and rhinitis; urological disorders such as urinary incontinence, pollakiuria, neurogenic or unstable bladder, cystospasm and chronic cystitis; gastrointestinal disorders such as irritable bowel syndrome, spastic colitis, diverticulitis and peptic ulceration; and cardiovascular disorders such as vagally induced sinus bradycardia
The present invention further provides a compound of formula (I) or a pharmaceutically acceptable composition comprising a compound of formula (I) for use in a method of treatment of the human or animal body by therapy, in particular for the treatment of respiratory, urological or gastrointestinal disease or disorder.
The present invention further provides the use of a compound of formula (I) or a pharmaceutically acceptable composition comprising a compound of formula (I) for the manufacture of a medicament for the treatment of a respiratory, urological or gastrointestinal disease or disorder.
Further, the compounds of formula (I) and pharmaceutical compositions comprising a compound of formula (I) can be used in a method of treating a respiratory, urological or gastrointestinal disease or disorder, which method comprises administering to a human or animal patient in need of such treatment an effective, non-toxic, amount of a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I).
Further, the compounds of formula (I) and pharmaceutical compositions comprising a compound of formula (I) can be used in combination with other drugs effective in the treatment of these diseases. The compounds of formula (I) may, for example be combined with β2 agonists, steroids, antiallergic drugs, phosphodiesterase IV inhibitors and/or leukotriene D4 (LTD4) inhibitors, for simultaneous, separate or sequential use in the treatment of a respiratory disease.
The title compound was synthesised according to methods c, and a from Intermediate I-1. The yield of the final step was 310 mg, 90.9%.
MS [M-Br]+: 374
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.72-2.07 (m, 4H), 2.28 (m, 1H), 3.07-3.56 (m, 5H), 3.78-3.99 (m, 3H), 5.19 (m, 1H), 5.52-5.68 (m, 2H), 5.89 (s, 1H), 5.98 (m, 1H), 7.01 (m, 2H), 7.12 (m, 2H), 7.50 (m, 2H).
The title compound was synthesised according to methods c, and a from Intermediate I-1. The yield of the final step was 270 mg, 72.9%.
m.p.: 163.5-165.1° C.
MS [M-Br]+: 416
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.62 (s, 3H), 1.67 (s, 3H), 1.73-2.03 (m, 4H), 2.20-2.43 (m, 3H), 3.05-3.46 (m, 6H), 3.52 (m, 1H), 3.92 (m, 1H), 4.98 (m, 1H), 5.18 (m, 1H), 5.89 (s, 1H), 7.01 (m, 2H), 7.13 (m, 2H), 7.50 (m, 2H).
The title compound was synthesised according to methods c, and a from Intermediate I-2. The yield of the final step was 260 mg, 77.2%.
m.p.: 156-158° C.
MS [M-Br]+: 388
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.65 (m, 1H), 1.80 (m, 1H), 1.95 (m, 2H), 2.08 (s, 3H), 2.28 (m, 1H), 3.06 (m, 1H), 3.25-3.52 (m, 4H), 3.82-4.05 (m, 3H), 5.20 (m, 1H), 5.53-5.67 (m, 2H), 5.97 (m, 1H), 7.01 (m, 2H), 7.10 (m, 2H), 7.51 (m, 2H).
The title compound was synthesised according to methods c, and a from Intermediate I-2. The yield of the final step was 380 mg, 100%.
m.p.: 130-131° C.
MS [M-Br]+: 430
1H-NMR (300 MHz, DMSO-de) δ ppm: 1.57-1.82 (m, 2H), 1.62 (s, 3H), 1.67 (s, 3H), 1.91 (m, 2H), 2.07 (s, 3H), 2.22-2.42 (m, 3H), 3.10 (m, 1H), 3.17 (m, 2H), 3.25-3.42 (m, 3H), 3.48 (m, 1H), 3.92 (m, 1H), 4.98 (m, 1H), 5.19 (m, 1H), 7.02 (m, 2H), 7.09 (m, 2H), 7.50 (m, 2H).
The title compound was synthesised according to methods c and b. The yield of the final step was 21.6 mg, 25.2%.
MS [M-CF3COO]+: 392
The title compound was synthesised according to methods c and b. The yield of the final step was 5.5 mg, 6.2%.
MS [M-CF3COO]+: 404
The title compound was synthesised according to methods c and b. The yield of the final step was 25.0 mg, 28.3%.
MS [M-CF3COO]+: 406
The title compound was synthesised according to methods c and a. The yield of the final step was 490 mg, 66.6%.
m.p.: 134° C.
MS [M-Br]+: 448
1H-NMR (300 MHz, CDCl3) δ ppm: 0.86 (t, 3H), 1.16-1.32 (m, 8H), 1.60 (m, 2H), 1.91 (m, 2H), 2.05 (m, 2H), 2.42 (m, 1H), 3.32-3.48 (m, 2H), 3.48-3.80 (m, 5H), 4.24 (m, 1H), 5.28 (m, 1H), 5.98 (s, 1H, OH), 6.95 (m, 2H), 7.17 (m, 1H), 7.22-7.28 (m, 3H).
The title compound was synthesised according to methods c and b. The yield of the final step was 23.4 mg, 24.6%.
MS [M-CF3COO]+: 446
The title compound was synthesised according to methods c and b. The yield of the final step was 12.6 mg, 12.6%.
MS [M-CF3COO]+: 474
The title compound was synthesised according to methods c and a. The yield of the final step was 400 mg, 70.0%.
m.p.: 176° C.
MS [M-Br]+: 390
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.77 (m, 2H), 1.92 (m, 2H), 2.31 (m, 1H), 3.15 (m, 1H), 3.20-3.52 (m, 4H), 3.81-4.01 (m, 3H), 5.24 (m, 1H), 5.53-5.68 (m, 2H), 5.96 (m, 1H), 7.02 (m, 2H), 7.16 (m, 2H), 7.48 (s, 1H, OH), 7.53 (m, 2H).
The title compound was synthesised according to methods c and a. The yield of the final step was 260 mg, 36.0%.
m.p.: 199° C.
MS [M-Br]+: 432
1H-NMR (300 MHz, CDCl3) δ ppm: 1.58 (s, 3H), 1.64 (m, 3H), 1.87 (m, 2H), 2.03 (m, 2H), 2.26-2.47 (m, 3H), 3.22-3.45 (m, 2H), 3.45-3.82 (m, 5H), 4.23 (m, 1H), 4.92 (m, 1H), 5.27 (m, 1H), 6.07 (s, 1H, OH), 6.93 (m, 2H), 7.15 (m, 1H), 7.24 (m, 3H).
The title compound was synthesised according to methods c and b. The yield of the final step was 14.5 mg, 14.2%.
MS [M-CF3COO]+: 486
The title compound was synthesised according to methods c and b. The yield of the final step was 16.6 mg, 19.3%.
MS [M-CF3COO]+: 394
The title compound was synthesised according to methods c and b. The yield of the final step was 16.0 mg, 18.0%.
MS [M-CF3COO]+: 408
The title compound was synthesised according to methods c and b. The yield of the final step was 6.5 mg, 7.1%.
MS [M-CF3COO]+: 422
The title compound was synthesised according to methods c and a. The yield of the final step was 220 mg, 31.0%.
m.p.: 155° C.
MS [M-Br]+: 422
1H-NMR (300 MHz, CDCl3) δ ppm: 1.15 (t, 3H), 1.88 (m, 2H), 2.03 (m, 2H), 2.46 (m, 1H), 3.49 (q, 2H), 3.54-3.96 (m, 8H), 4.06 (m, 1H), 4.31 (m, 1H), 5.27 (m, 1H), 5.73 (s, 1H, OH), 6.97 (m, 2H), 7.20 (m, 1H), 7.22-7.33 (m, 3H).
The title compound was synthesised according to methods c and a. The yield of the final step was 580 mg, 14.0%.
m.p.: 156° C.
MS [M-Cl]+: 438
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.72 (m, 2H), 1.92 (m, 2H), 2.27 (m, 1H), 3.10-3.70 (m, 11H), 3.79 (m, 2H), 3.96 (m, 1H), 4.72 (m, 1H), 5.21 (m, 1H), 6.97 (m, 2H), 7.15 (m, 2H), 7.51 (m, 3H).
The title compound was synthesised according to methods c and a. The yield of the final step was 260 mg, 35.0%.
MS [M-Br]+: 452
1H-NMR (300 MHz, CDCl3) δ ppm: 1.87 (m, 2H), 2.04 (m, 2H), 2.44 (m, 1H), 3.32 (s, 3H), 3.48 (m, 2H), 3.54-3.96 (m, 10H), 3.98-4.08 (m, 1H), 4.30 (m, 1H), 5.26 (m, 1H), 6.0 (b.s., 1H, OH), 6.97 (m, 2H), 7.20 (m, 1H), 7.23-7.32 (m, 3H).
The title compound was synthesised according to methods c and a. The yield of the final step was 240 mg, 35.0%.
MS [M-Br]+: 406
The title compound was synthesised according to methods c and b. The yield of the final step was 15.7 mg, 16.4%.
MS [M-CF3COO]+: 450
The title compound was synthesised according to methods c and b. The yield of the final step was 7.9 mg, 7.8%.
MS [M-CF3COO]+: 482
The title compound was synthesised according to methods c and b. The yield of the final step was 17.1 mg, 17.4%.
MS [M-CF3COO]+: 464
The title compound was synthesised according to methods c and b. The yield of the final step was 15.1 mg, 15.4%.
MS [M-CF3COO]+: 464
The title compound was synthesised according to methods c and b. The yield of the final step was 15.0 mg, 14.9%.
MS [M-CF3COO]+: 478
The title compound was synthesised according to methods c and b. The yield of the final step was 10.7 mg, 10.9%.
MS [M-CF3COO]+: 464
The title compound was synthesised according to methods c and b. The yield of the final step was 14.0 mg, 15.5%.
MS [M-CF3COO]+: 417
The title compound was synthesised according to methods c and b. The yield of the final step was 16.2 mg, 17.5%.
MS [M-CF3COO]+: 431
The title compound was synthesised according to methods c and b. The yield of the final step was 19.1 mg, 19.6%.
MS [M-CF3COO]+: 459
The title compound was synthesised according to methods c and b. The yield of the final step was 18.4 mg, 18.8%.
MS [M-CF3COO]+: 460
The title compound was synthesised as a mixture of diastereomers according to methods f and a. The yield of the final step was 350 mg, 50.0%.
m.p.: 170° C.
MS [M-Br]+: 384
1H-NMR (300 MHz, DMSO-d6) δ ppm: (mixture of diastereomers) 1.46-1.79 (m, 2H), 1.81-2.02 (m, 2H), 2.28 (m, 1H), 3.07 (m, 1H), 3.17-3.46 (m, 4H), 3.80-4.0 (m, 3H), 5.23 (m, 1H), 5.53-5.67 (m, 2H), 5.96 (m, 1H), 7.03 (m, 1H), 7.12 (m, 1H), 7.20 (s, 1H, OH), 7.29-7.42 (m, 3H), 7.42-7.49 (m, 2H), 7.53 (m, 1H).
The title compound was synthesised as a mixture of diastereomers according to methods c and a. The yield of the final step was 120 mg, 88.8%.
MS [M-Br]+: 368
1H-NMR (300 MHz, DMSO-d6) δ ppm: (mixture of diastereomers) 1.45-1.80 (m, 2H), 1.80-2.03 (m, 2H), 2.26 (m, 1H), 2.95-3.24 (m, 2H), 3.24-3.47 (m, 3H), 3.75-3.98 (m, 3H), 5.20 (m, 1H), 5.52-5.67 (m, 2H), 5.96 (m, 1H), 6.28 (dd, 1H), 6.46 (m, 1H), 6.95 (d, 1H, OH), 7.31-7.45 (m, 3H), 7.48 (m, 2H), 7.68 (m, 1H).
The title compound was synthesised as a mixture of diastereomers according to methods c and a. The yield of the final step was 170 mg, 62.9%.
MS [M-Br]+: 374
1H-NMR (300 MHz, DMSO-d6) δ ppm: (mixture of diastereomers) 1.58-1.83 (m, 2H), 1.83-2.06 (m, 2H), 2.28 (m, 1H), 3.06 (m, 1H), 3.18 (m, 1H), 3.25-3.54 (m, 3H), 3.78-4.02 (m, 3H), 5.22 (m, 1H), 5.52-5.68 (m, 2H), 5.97 (m, 1H), 6.33 (dd, 1H), 6.46 (m, 1H), 7.04 (m, 1H), 7.15 (m, 1H), 7.29 (d, 1H), 7.55 (m, 1H), 7.69 (m, 1H).
The title compound was synthesised according to methods c and a. The yield of the final step was 180 mg, 88.2%.
m.p.: 75.2-76.8° C.
MS [M-Br]+: 374
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.54 (m, 1H), 1.69 (m, 1H), 1.76 (s, 3H), 1.87 (m, 2H), 2.11 (m, 1H), 3.00 (m, 1H), 3.16-3.47 (m, 4H), 3.79 (m, 1H), 3.91 (m, 2H), 4.99 (m, 1H), 5.52-5.66 (m, 2H), 5.93 (m, 1H), 7.30-7.50 (m, 4H), 7.64 (d, 1H), 7.72 (d, 1H), 7.90 (d, 2H).
The title compound was synthesised according to methods c, and a from Intermediate I-3. The yield of the final step was 550 mg, 80.3%.
m.p.: 260° C.
MS [M-Br]+: 376
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.40 (m, 1H), 1.64 (m, 1H), 1.85 (m, 2H), 2.08 (m, 1H), 2.77 (m, 1H), 3.03 (m, 1H), 3.17-3.41 (m, 3H), 3.70-3.94 (m, 3H), 5.03 (m, 1H), 5.50-5.68 (m, 2H), 5.90 (m, 1H), 6.85 (s, 1H, OH), 7.35 (m, 2H), 7.46 (m, 2H), 7.60 (m, 2H), 7.83 (d, 2H).
The title compound was synthesised according to methods c, and a from Intermediate I-3. The yield of the final step was 490 mg, 65.5%.
m.p.: 192.4-193.1° C.
MS [M-Br]+: 418
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.40 (m, 1H), 1.55-1.72 (m, 1H), 1.61 (s, 3H), 1.66 (s, 3H), 1.84 (m, 2H), 2.04 (m, 1H), 2.26 (m, 2H), 2.76 (m, 1H), 2.98-3.16 (m, 3H), 3.18-3.45 (m, 3H), 3.79 (m, 1H), 4.95 (m, 1H), 5.01 (m, 1H), 6.82 (s, 1H, OH), 7.33 (m, 2H), 7.44 (m, 2H), 7.59 (m, 2H), 7.82 (d, 2H).
The title compound was synthesised according to methods c, and a from Intermediate I-3. The yield of the final step was 330 mg, 85.5%.
m.p.: 214.9-216.6° C.
MS [M-Br]+: 434
1H-NMR (300 MHz, DMSO-d6) δ ppm: 0.88 (t, 3H), 1.12-1.70 (m, 12H), 1.70-1.93 (m, 2H), 2.04 (m, 1H), 2.78 (m, 1H), 2.96-3.18 (m, 3H), 3.18-3.48 (m, 3H), 3.77 (m, 1H), 5.01 (m, 1H), 6.84 (s, 1H, OH), 7.34 (m, 2H), 7.45 (m, 2H), 7.61 (m, 2H), 7.84 (d, 2H).
The title compound was synthesised according to methods c, and a from Intermediate I-3. The yield of the final step was 270 mg, 38.0%.
MS [M-Br]+: 392
The title compound was synthesised according to methods c, and a from Intermediate I-3. The yield of the final step was 610 mg, 78.2%.
m.p.: 194° C.
MS [M-Br]+: 438
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.44 (m, 1H), 1.64 (m, 1H), 1.85 (m, 2H), 2.09 (m, 1H), 2.93 (m, 1H), 3.18-3.28 (m, 1H), 3.26 (s, 3H), 3.30-3.60 (m, 9H), 3.73 (m, 2H), 3.88 (m, 1H), 5.00 (m, 1H), 6.83 (s, 1H, OH), 7.35 (m, 2H), 7.45 (m, 2H), 7.61 (m, 2H), 7.83 (d, 2H).
The title compound was synthesised according to methods c, and a from Intermediate I-3. The yield of the final step was 660 mg, 85.7%.
m.p.: 62° C.
MS [M-Br]+: 436
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.43 (m, 1H), 1.64 (m, 1H), 1.71-2.15 (m, 5H), 2.86 (m, 1H), 3.0-3.64 (m, 8H), 3.74-3.97 (m, 3H), 4.89 (m, 1H), 5.00 (s, 1H), 7.34 (m, 2H), 7.45 (m, 2H), 7.63 (m, 2H), 7.82 (d, 2H).
The title compound was synthesised according to methods d and a. The yield of the final step was 170 mg, 51.5%.
m.p.: 57° C.
MS [M-Br]+: 376
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.63-2.00 (m, 4H), 2.17 (m, 1H), 3.06-3.56 (m, 5H), 3.77 (m, 1H), 3.92 (m, 2H), 5.03 (m, 1H), 5.30 (s, 1H), 5.50-5.70 (m, 2H), 5.94 (m, 1H), 7.20 (m, 4H), 7.38 (m, 2H), 7.50 (m, 2H).
The title compound was synthesised according to methods d and a. The yield of the final step was 270 mg, 72.9%.
m.p.: 225° C.
MS [M-Br]+: 418
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.60-2.0 (m, 4H), 1.64 (s, 3H), 1.69 (s, 3H), 2.16 (m, 1H), 2.32 (m, 2H), 3.10-3.46 (m, 6H), 3.53 (m, 1H), 3.85 (m, 1H), 4.93-5.08 (m, 2H), 5.32 (s, 1H), 7.19 (m, 4H), 7.38 (m, 2H), 7.52 (m, 2H).
The title compound was synthesised according to methods c and a. The yield of the final step was 1.04 g, 73.8%.
m.p.: 64.3-67.8° C.
MS [M-Br]+: 390
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.35 (m, 1H), 1.65 (m, 1H), 1.73-1.91 (m, 2H), 1.89 (s, 3H), 2.11 (m, 1H), 2.75 (m, 1H), 3.00 (m, 1H), 3.15-3.45 (m, 3H), 3.70-3.90 (m, 3H), 5.03 (m, 1H), 5.50-5.65 (m, 2H), 5.86 (m, 1H), 7.12-7.19 (m, 4H), 7.35 (m, 2H), 7.42 (m, 2H).
The title compound was synthesised according to methods c and a. The yield of the final step was 270 mg, 67.5%.
m.p.: 232° C.
MS [M-Br]+: 392
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.29 (m, 1H), 1.62 (m, 1H), 1.70-1.94 (m, 2H), 2.06 (m, 1H), 2.62 (m, 1H), 2.79 (m, 1H), 3.13-3.42 (m, 3H), 3.64-3.87 (m, 3H), 5.02 (m, 1H), 5.47-5.65 (m, 2H), 5.81 (m, 1H), 7.18 (s, 1H, OH), 7.25 (m, 4H), 7.44 (m, 2H), 7.65 (m, 2H).
The title compound was synthesised according to methods c and a. The yield of the final step was 315 mg, 90.5%.
m.p.: 87.6-89.1° C.
MS [M-Br]+: 410
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.28 (m, 1H), 1.50-1.95 (m, 5H), 2.05 (m, 1H), 2.63 (m, 1H), 2.83 (m, 1H), 3.10-3.50 (m, 7H), 3.73 (m, 1H), 4.76 (t, 1H, OH), 5.0 (m, 1H), 7.18 (s, 1H, OH), 7.18-7.30 (m, 4H), 7.40-7.50 (m, 2H), 7.60-7.70 (m, 2H).
The title compound was synthesised according to methods d, and a from Intermediate I-4. The yield of the final step was 260 mg, 95.6%.
m.p.: 219.5-220.3° C.
MS [M-Br]+: 388
1H-NMR (300 MHz, CDCl3) δ ppm: 1.52 (m, 1H), 1.71 (m, 1H), 1.93 (m, 2H), 2.20 (m, 1H), 2.79-2.94 (m, 2H), 3.02 (m, 1H), 3.11-3.31 (m, 2H), 3.40-3.52 (m, 1H), 3.52-3.75 (m, 3H), 4.06-4.39 (m, 3H), 5.10 (m, 1H), 5.21 (s, 1H), 5.57-5.87 (m, 3H), 7.16 (m, 6H), 7.39 (m, 2H).
The title compound was synthesised according to methods d, and a from Intermediate I-4. The yield of the final step was 290 mg, 97.9%.
m.p.: 216° C.
MS [M-Br]+: 430
1H-NMR (300 MHz, CDCl3) δ ppm: 1.53 (m, 1H), 1.62 (s, 3H), 1.67 (s, 3H), 1.81 (m, 1H), 1.98 (m, 2H), 2.18-2.35 (m, 3H), 2.75-2.98 (m, 3H), 3.11-3.46 (m, 5H), 3.54-3.76 (m, 3H), 4.20 (m, 1H), 4.95 (m, 1H), 5.14 (s, 1H), 5.10-5.20 (m, 1H), 7.19 (m, 6H), 7.36 (m, 2H).
The title compound was synthesised according to methods f, and a from Intermediate I-6a. The yield of the final step was 250 mg, 75.7%.
m.p.: 180° C.
MS [M-Br]+: 392
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.72 (m, 2H), 1.92 (m, 2H), 2.21 (m, 1H), 3.02 (m, 1H), 3.11 (m, 1H), 3.18-3.52 (m, 5H), 3.74 (m, 1H), 3.84 (m, 2H), 5.04 (m, 1H), 5.49-5.64 (m, 2H), 5.90 (m, 1H), 6.15 (s, 1H, OH), 7.14 (m, 5H), 7.23-7.40 (m, 3H), 7.53 (m, 2H).
(*) Configuration not assigned
The title compound was synthesised according to methods f, and a from Intermediate I-6a. The yield of the final step was 280 mg, 77.7%.
m.p.: 224° C.
MS [M-Br]+: 434
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.61 (s, 3H), 1.67 (s, 3H), 1.63-1.75 (m, 2H), 1.75-2.00 (m, 2H), 2.21 (m, 1H), 2.28 (m, 2H), 2.99-3.20 (m, 4H), 3.20-3.50 (m, 5H), 3.77 (m, 1H), 4.97 (m, 1H), 5.04 (m, 1H), 6.14 (s, 1H, OH), 7.14 (m, 5H), 7.23-7.39 (m, 3H), 7.54 (m, 2H).
(*) Configuration not assigned
The title compound was synthesised as a mixture of diastereomers according to methods c and a. The yield of the final step was 210 mg, 61.8%.
m.p.: 62.6-63.9° C.
MS [M-Br]+: 348
1H-NMR (300 MHz, DMSO-d6) δ ppm: (mixture of diastereomers) 1.68-2.05 (m, 4H), 2.26 (m, 1H), 2.76 (m, 1H), 2.95 (m, 1H), 3.08-3.53 (m, 5H), 3.74-4.00 (m, 3H), 5.02-5.21 (m, 3H), 5.51-5.67 (m, 2H), 5.78 (m, 1H), 5.97 (m, 1H), 6.49 (d, 1H, OH), 7.01 (m, 1H), 7.15 (m, 1H), 7.48 (m, 1H)
The title compound was synthesised as a mixture of diastereomers according to methods c and a. The yield of the final step was 290 mg, 78.4%.
m.p.: 56.2-57.9° C.
MS [M-Br]+: 390
1H-NMR (300 MHz, DMSO-d6) δ ppm: (mixture of diastereomers) 1.52-2.06 (m, 4H), 1.63 (d, 3H), 1.69 (s, 3H), 2.16-2.43 (m, 3H), 2.78 (dd, 1H), 2.96 (m, 1H), 3.07-3.59 (m, 7H), 3.88 (m, 1H), 4.92-5.23 (m, 4H), 5.78 (m, 1H), 6.48 (d, 1H, OH), 7.01 (m, 1H), 7.15 (m, 1H), 7.46 (m, 1H).
The title compound was synthesised according to methods f and a. The yield of the final step was 180 mg, 78.3%.
m.p.: 68.2-70.1° C.
MS [M-Br]+: 376
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.26-1.66 (m, 8H), 1.78-2.08 (m, 4H), 2.30 (m, 1H), 2.81 (m, 1H), 3.14 (m, 1H), 3.20-3.58 (m, 4H), 3.78-4.03 (m, 3H), 5.15 (m, 1H), 5.52-5.68 (m, 2H), 5.97 (m, 1H), 6.18 (s, 1H, OH), 7.01 (m, 1H), 7.16 (d, 1H), 7.45 (d, 1H).
The title compound was synthesised according to methods f and a. The yield of the final step was 290 mg, 71.7%.
m.p.: 84° C.
MS [M-Br]+: 418
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.19-1.76 (m, 8H), 1.63 (s, 3H), 1.68 (s, 3H), 1.77-2.05 (m, 4H), 2.20-2.42 (m, 3H), 2.81 (m, 1H), 3.11-3.24 (m, 3H), 3.24-3.61 (m, 4H), 3.89 (m, 1H), 5.01 (m, 1H), 5.14 (m, 1H), 6.19 (s, 1H, OH), 7.00 (m, 1H), 7.16 (d, 1H), 7.44 (d, 1H).
The title compound was synthesised according to methods c and a. The yield of the final step was 230 mg, 85.2%.
m.p.: 65.3-66.0° C.
MS [M-Br]+: 376
1H-NMR (300 MHz, DMSO-d6) δ ppm: (mixture of diastereomers (3R,2R):(3R,2S) 72:28) 1.30-1.66 (m, 8H), 1.67-2.05 (m, 4H), 2.23 and 2.30 (m, 1H), 2.83 (m, 1H), 3.06-3.55 (m, 5H), 3.74-4.03 (m, 3H), 5.14 (m, 1H), 5.53-5.68 (m, 2H), 5.99 (m, 1H), 6.18 and 6.19 (s, 1H, OH), 7.00 (m, 1H), 7.16 (m, 1H), 7.44 (m, 1H).
The title compound was synthesised according methods f and a. The crude mixture was purified by reverse chromatography eluting the product with water. The yield of the final step was 148 mg, 66%.
MS [M-Br]+: 380
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.25-1.99 (m, 12H), 2.29 (m, 1H), 2.75-2.85 (m, 1H), 3.30-3.60 (m, 7H), 5.13 (m, 1H), 5.29-5.32 (t, 1H), 6.21 (s, 1H), 6.98-7.01 (dd, 1H), 7.13-7.15 (dd, 1H), 7.42-7.44 (dd, 1H)
The title compound was synthesised according methods f and a. The crude mixture was purified by reverse chromatography eluting the product with water. The yield of the final step was 145 mg, 53%.
MS [M-Br]+: 394
The title compound was synthesised according methods f and a. The crude mixture was purified by reverse chromatography eluting the product with water. The yield of the final step was 40 mg, 20%.
MS [M-Br]+: 408
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.25-1.93 (m, 18H), 2.29 (m, 1H), 2.81 (m, 1H), 3.08-3.48 (m, 5H), 3.75-3.90 (m, 1H), 4.61-4.64 (tm 1H), 5.10-5.20 (m, 1H), 6.23 (s, 1H), 6.99-7.02 (t, 1H), 7.14-7.16 (m, 1H), 7.43-7.45 (d, 1H)
The title compound was synthesised according methods f and a. The crude mixture was purified by reverse chromatography eluting the product with water. The yield of the final step was 110 mg, 37%.
MS [M-Br]+: 424
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.10-1.53 (m, 14H), 1.82-2.04 (m, 3H), 2.17-2.37 (m, 1H), 2.76-2.87 (m, 1H), 3.23-3.51 (m, 5H), 3.79-3.95 (m, 2H), 4.67-4.71 (t, 1H), 5.09-5.19 (m, 1H), 6.20 (s, 1H), 6.99-7.01 (dd, 1H), 7.14-7.16 (m, 1H), 7.42-7.44 (dd, 1H)
The title compound was synthesised according methods f and a. The crude mixture was purified by reverse chromatography eluting the product with water. The yield of the final step was 90 mg, 35%.
MS [M-Br]+: 436
1H-NMR (300 MHz, DMSO-d6) δ ppm: 1.20-2.00 (m, 20H), 2.28 (m, 1H), 2.81 (m, 1H), 3.10-3.50 (m, 9H), 3.81 (m, 1H), 4.38-4.41 (t, 1H), 5.12 (m, 1H), 6.20 (s, 1H), 6.69-7.02 (t, 1H), 7.14-7.15 (m, 1H), 7.43-7.46 (m, 1H)
The following examples illustrate pharmaceutical compositions according to the present invention and procedures for their preparation.
Using a mixer machine, 15 g of the compound of the present invention was mixed with 340.8 g of lactose and 85.2 g of microcrystalline cellulose. The mixture was subjected to compression moulding using a roller compactor to give a flake-like compressed material. The flake-like compressed material was pulverized using a hammer mill, and the pulverized material was screened through a 20 mesh screen. A 4.5 g portion of light silicic anhydride and 4.5 g of magnesium stearate were added to the screened material and mixed. The mixer product was subjected to a tablets making machine equipped with a die/punch system of 7.5 mm in diameter, thereby obtaining 3,000 tablets each having 150 mg in weight.
Using a fluidized bed granulating machine, 15 g of the compound of the present invention was mixed with 285.6 g of lactose and 122.4 g of corn starch. Separately, 22.5 g of polyvinylpyrrolidone was dissolved in 127.5 g of water to prepare a binding solution. Using a fluidized bed granulating machine, the binding solution was sprayed on the above mixture to give granulates. A 4.5 g portion of magnesium stearate was added to the obtained granulates and mixed. The obtained mixture was subjected to a tablet making machine equipped with a die/punch biconcave system of 6.5 mm in diameter, thereby obtaining 3,000 tablets, each having 150 mg in weight.
Separately, a coating solution was prepared by suspending 6.9 g of hydroxypropylmethylcellulose 2910, 1.2 g of polyethylene glycol 6000, 3.3 g of titanium dioxide and 2.1 g of purified talc in 72.6 g of water. Using a High Coated, the 3,000 tablets prepared above were coated with the coating solution to give film-coated tablets, each having 154.5 mg in weight.
A 40 mg portion of the compound of the present invention was dissolved in 90 ml of physiological saline, and the solution was adjusted to a total volume of 100 ml with the same saline solution, dispensed in 1 ml portions into 1 ml capacity ampoule and then sterilized at 115° for 30 minutes to give liquid inhalant.
A 20 g portion of the compound of the present invention was uniformly mixed with 400 g of lactose, and a 200 mg portion of the mixture was packed in a powder inhaler for exclusive use to produce a powder inhalant.
The active ingredient concentrate is prepared by dissolving 0.0480 g of the compound of the present invention in 2.0160 g of ethyl alcohol. The concentrate is added to an appropriate filling apparatus. The active ingredient concentrate is dispensed into aerosol container, the headspace of the container is purged with Nitrogen or HFC-134A vapor (purging ingredients should not contain more than 1 ppm oxygen) and is sealed with valve. 11.2344 g of HFC-134A propellant is then pressure filled into the sealed container
| Number | Date | Country | Kind |
|---|---|---|---|
| P 200400638 | Mar 2004 | ES | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2005/002523 | 3/10/2005 | WO | 00 | 3/20/2008 |
